{"DataElement":{"publicId":"7840173","version":"1","preferredName":"Treatment Regimen Targeted Therapy AALL1621 Targeted Therapy Type","preferredDefinition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment._A type of treatment that uses drugs or other substances, such as monoclonal antibodies, to identify and attack specific cancer cells. Targeted therapy may have fewer side effects than other types of cancer treatments._Something distinguishable as an identifiable class based on common qualities._The use of synthetic or naturally-occurring chemicals for the treatment of diseases._A type of treatment that uses drugs or other substances, such as monoclonal antibodies, to identify and attack specific cancer cells. Targeted therapy may have fewer side effects than other types of cancer treatments.","longName":"TARG_RGM_TP","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7840172","version":"1","preferredName":"Treatment Regimen Targeted Therapy","preferredDefinition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment._A type of treatment that uses drugs or other substances, such as monoclonal antibodies, to identify and attack specific cancer cells. Targeted therapy may have fewer side effects than other types of cancer treatments.","longName":"TAR_TP_RGM","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"5053414","version":"1","preferredName":"Targeted Therapy","preferredDefinition":"A type of treatment that uses drugs or other substances, such as monoclonal antibodies, to identify and attack specific cancer cells. Targeted therapy may have fewer side effects than other types of cancer treatments.","longName":"C93352","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Targeted Therapy","conceptCode":"C93352","definition":"A type of cancer treatment that uses testing and medication to more precisely identify and treat cancer. These treatments target and disable genes or proteins necessary to the proliferation of cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"253E4726-4DEF-FF89-E050-BB89AD436EE9","latestVersionIndicator":"Yes","beginDate":"2015-11-23","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-11-23","modifiedBy":"ONEDATA","dateModified":"2015-11-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177402","version":"1","preferredName":"Regimen","preferredDefinition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","longName":"Regimen","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-527D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D10559ED-9F3E-37E6-E053-4EBD850ADE5E","latestVersionIndicator":"Yes","beginDate":"2021-11-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-11-17","modifiedBy":"ONEDATA","dateModified":"2021-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7840170","version":"1","preferredName":"AALL1621 Targeted Therapy Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities._The use of synthetic or naturally-occurring chemicals for the treatment of diseases._A type of treatment that uses drugs or other substances, such as monoclonal antibodies, to identify and attack specific cancer cells. Targeted therapy may have fewer side effects than other types of cancer treatments.","longName":"7840170v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"20","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Venetoclax","valueDescription":"Venetoclax","ValueMeaning":{"publicId":"5944045","version":"1","preferredName":"Venetoclax","longName":"5944045","preferredDefinition":"An orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in some cancers and plays an important role in the regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Compared to the Bcl-2 inhibitor navitoclax, this agent does not inhibit bcl-XL and does not cause bcl-XL-mediated thrombocytopenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Venetoclax","conceptCode":"C103147","definition":"An orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in some cancers and plays an important role in the regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Compared to the Bcl-2 inhibitor navitoclax, this agent does not inhibit bcl-XL and does not cause bcl-XL-mediated thrombocytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57E65346-8D8B-6C22-E053-F662850A5722","latestVersionIndicator":"Yes","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1055049-105F-52B2-E053-4EBD850A5EA0","beginDate":"2021-11-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-11-17","modifiedBy":"ONEDATA","dateModified":"2021-11-17","deletedIndicator":"No"},{"value":"Palbociclib","valueDescription":"PD-0332991","ValueMeaning":{"publicId":"3564160","version":"1","preferredName":"PD-0332991","longName":"3564160","preferredDefinition":"An orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. PD-0332991 selectively inhibits cyclin-dependent kinases (particularly Cdk4/cyclin D1 kinase), which may inhibit retinoblastoma (Rb) protein phosphorylation; inhibition of Rb phosphorylation prevents Rb-positive tumor cells from entering the S phase of the cell cycle (arrest in the G1 phase), resulting in suppression of DNA replication and decreased tumor cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Palbociclib","conceptCode":"C49176","definition":"An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7DBA78C-8B81-5111-E040-BB89AD4317C1","latestVersionIndicator":"Yes","beginDate":"2012-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-22","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1055049-1069-52B2-E053-4EBD850A5EA0","beginDate":"2021-11-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-11-17","modifiedBy":"ONEDATA","dateModified":"2021-11-17","deletedIndicator":"No"},{"value":"Ribociclib","valueDescription":"Ribociclib","ValueMeaning":{"publicId":"6072178","version":"1","preferredName":"Ribociclib","longName":"6072178","preferredDefinition":"An orally available cyclin-dependent kinase (CDK) inhibitor targets at cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. Ribociclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ribociclib","conceptCode":"C95701","definition":"An orally available cyclin-dependent kinase (CDK) inhibitor targets at cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. Ribociclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65344B1A-4E61-24A6-E053-F662850A121F","latestVersionIndicator":"Yes","beginDate":"2018-02-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-02-14","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1055049-1073-52B2-E053-4EBD850A5EA0","beginDate":"2021-11-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-11-17","modifiedBy":"ONEDATA","dateModified":"2021-11-17","deletedIndicator":"No"},{"value":"Ixazomib","valueDescription":"Ixazomib","ValueMeaning":{"publicId":"5944043","version":"1","preferredName":"Ixazomib","longName":"5944043","preferredDefinition":"An active metabolite of MLN9708, a second generation, boron containing peptide proteasome inhibitor (PI) with potential antineoplastic activity. Ixazomib binds to and inhibits the 20S catalytic core of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins; disruption of various cell signaling pathways may follow, resulting in the induction of apoptosis. Compared to first generation PIs, second generation PIs may have an improved pharmacokinetic profile with increased potency and less toxicity. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ixazomib","conceptCode":"C97940","definition":"An active metabolite of MLN9708, a second generation, boron containing peptide proteasome inhibitor (PI) with potential antineoplastic activity. Ixazomib binds to and inhibits the 20S catalytic core of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins; disruption of various cell signaling pathways may follow, resulting in the induction of apoptosis. Compared to first generation PIs, second generation PIs may have an improved pharmacokinetic profile with increased potency and less toxicity. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57E60930-FED1-69F8-E053-F662850ABC19","latestVersionIndicator":"Yes","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1055049-107D-52B2-E053-4EBD850A5EA0","beginDate":"2021-11-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-11-17","modifiedBy":"ONEDATA","dateModified":"2021-11-17","deletedIndicator":"No"},{"value":"Bortezomib","valueDescription":"Bortezomib","ValueMeaning":{"publicId":"5127395","version":"1","preferredName":"Bortezomib","longName":"5127395","preferredDefinition":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bortezomib","conceptCode":"C1851","definition":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FA1B-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1055049-1087-52B2-E053-4EBD850A5EA0","beginDate":"2021-11-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-11-17","modifiedBy":"ONEDATA","dateModified":"2021-11-17","deletedIndicator":"No"},{"value":"Ruxolitinib","valueDescription":"Ruxolitinib","ValueMeaning":{"publicId":"5125106","version":"1","preferredName":"Ruxolitinib","longName":"5125106","preferredDefinition":"An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ruxolitinib","conceptCode":"C77888","definition":"An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C0D42D8-A87E-AEAF-E050-BB89AD430679","latestVersionIndicator":"Yes","beginDate":"2016-02-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1055049-1091-52B2-E053-4EBD850A5EA0","beginDate":"2021-11-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-11-17","modifiedBy":"ONEDATA","dateModified":"2021-11-17","deletedIndicator":"No"},{"value":"Ponatinib","valueDescription":"Ponatinib","ValueMeaning":{"publicId":"3776076","version":"1","preferredName":"Ponatinib","longName":"3776076","preferredDefinition":"An orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ponatinib","conceptCode":"C95777","definition":"An orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE84372B-DC57-3F77-E040-BB89AD432E57","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1055049-109B-52B2-E053-4EBD850A5EA0","beginDate":"2021-11-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-11-17","modifiedBy":"ONEDATA","dateModified":"2021-11-17","deletedIndicator":"No"},{"value":"Dasatinib","valueDescription":"Dasatinib","ValueMeaning":{"publicId":"2737464","version":"1","preferredName":"Dasatinib","longName":"2737464","preferredDefinition":"An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dasatinib","conceptCode":"C38713","definition":"An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C312-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1055049-10A5-52B2-E053-4EBD850A5EA0","beginDate":"2021-11-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-11-17","modifiedBy":"ONEDATA","dateModified":"2021-11-17","deletedIndicator":"No"},{"value":"Imatinib","valueDescription":"Imatinib","ValueMeaning":{"publicId":"3228378","version":"1","preferredName":"Imatinib","longName":"3228378","preferredDefinition":"An antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.  Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST).  This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imatinib","conceptCode":"C62035","definition":"An antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.  Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST).  This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A160434C-66D5-A92B-E040-BB89AD43423D","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1055049-10AF-52B2-E053-4EBD850A5EA0","beginDate":"2021-11-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-11-17","modifiedBy":"ONEDATA","dateModified":"2021-11-17","deletedIndicator":"No"},{"value":"Other, specify","valueDescription":"Other","ValueMeaning":{"publicId":"2559666","version":"1","preferredName":"Other","longName":"2559666","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B61F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"LISU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1055049-10B9-52B2-E053-4EBD850A5EA0","beginDate":"2021-11-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-11-17","modifiedBy":"ONEDATA","dateModified":"2021-11-17","deletedIndicator":"No"},{"value":"Multi-targeted protein kinase inhibitors (Sorafenib)","valueDescription":"Multi-targeted protein kinase inhibitors (Sorafenib)","ValueMeaning":{"publicId":"8067802","version":"1","preferredName":"Multi-targeted protein kinase inhibitors (Sorafenib)","longName":"8067802","preferredDefinition":"Multi-targeted protein kinase inhibitors (Sorafenib)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D93CE5B6-8705-2C7A-E053-4EBD850AAD5C","latestVersionIndicator":"Yes","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D93CE5B6-871E-2C7A-E053-4EBD850AAD5C","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","deletedIndicator":"No"},{"value":"FLT3 (fms-like tyrosine kinase 3) inhibitors (Gilteritinib)","valueDescription":"FLT3 (fms-like tyrosine kinase 3) inhibitors (Gilteritinib)","ValueMeaning":{"publicId":"8067803","version":"1","preferredName":"FLT3 (fms-like tyrosine kinase 3) inhibitors (Gilteritinib)","longName":"8067803","preferredDefinition":"FLT3 (fms-like tyrosine kinase 3) inhibitors (Gilteritinib)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D93CE5B6-8728-2C7A-E053-4EBD850AAD5C","latestVersionIndicator":"Yes","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D93CE5B6-8741-2C7A-E053-4EBD850AAD5C","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","deletedIndicator":"No"},{"value":"Bcl-2(B-cell lymphoma 2) inhibitors (Venetoclax)","valueDescription":"Bcl-2(B-cell lymphoma 2) inhibitors (Venetoclax)","ValueMeaning":{"publicId":"8067804","version":"1","preferredName":"Bcl-2(B-cell lymphoma 2) inhibitors (Venetoclax)","longName":"8067804","preferredDefinition":"Bcl-2(B-cell lymphoma 2) inhibitors (Venetoclax)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D93CE5B6-874B-2C7A-E053-4EBD850AAD5C","latestVersionIndicator":"Yes","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D93CE5B6-8764-2C7A-E053-4EBD850AAD5C","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","deletedIndicator":"No"},{"value":"Janus Kinase (JAK) inhibitors (Ruxolitinib)","valueDescription":"Janus Kinase (JAK) inhibitors (Ruxolitinib)","ValueMeaning":{"publicId":"8067805","version":"1","preferredName":"Janus Kinase (JAK) inhibitors (Ruxolitinib)","longName":"8067805","preferredDefinition":"Janus Kinase (JAK) inhibitors (Ruxolitinib)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D93CE5B6-876E-2C7A-E053-4EBD850AAD5C","latestVersionIndicator":"Yes","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D93CE5B6-8787-2C7A-E053-4EBD850AAD5C","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","deletedIndicator":"No"},{"value":"mTOR inhibitors (Everolimus, Sirolimus, Temsirolimus)","valueDescription":"mTOR inhibitors (Everolimus, Sirolimus, Temsirolimus)","ValueMeaning":{"publicId":"8067806","version":"1","preferredName":"mTOR inhibitors (Everolimus, Sirolimus, Temsirolimus)","longName":"8067806","preferredDefinition":"mTOR inhibitors (Everolimus, Sirolimus, Temsirolimus)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D93CE5B6-8791-2C7A-E053-4EBD850AAD5C","latestVersionIndicator":"Yes","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D93CE5B6-87AA-2C7A-E053-4EBD850AAD5C","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","deletedIndicator":"No"},{"value":"Phosphatidylinositol-3-kinase (PI3K) inhibitors (Copanlisib, Idelalisib)","valueDescription":"Phosphatidylinositol-3-kinase (PI3K) inhibitors (Copanlisib, Idelalisib)","ValueMeaning":{"publicId":"8067807","version":"1","preferredName":"Phosphatidylinositol-3-kinase (PI3K) inhibitors (Copanlisib, Idelalisib)","longName":"8067807","preferredDefinition":"Phosphatidylinositol-3-kinase (PI3K) inhibitors (Copanlisib, Idelalisib)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D93CE5B6-87B4-2C7A-E053-4EBD850AAD5C","latestVersionIndicator":"Yes","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D93CE5B6-87CD-2C7A-E053-4EBD850AAD5C","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","deletedIndicator":"No"},{"value":"BCR-ABL tyrosine kinase inhibitors (Bosutinib, Dasatinib, Imatinib, Nilotinib, Ponatinib)","valueDescription":"BCR-ABL tyrosine kinase inhibitors (Bosutinib, Dasatinib, Imatinib, Nilotinib, Ponatinib)","ValueMeaning":{"publicId":"8067808","version":"1","preferredName":"BCR-ABL tyrosine kinase inhibitors (Bosutinib, Dasatinib, Imatinib, Nilotinib, Ponatinib)","longName":"8067808","preferredDefinition":"BCR-ABL tyrosine kinase inhibitors (Bosutinib, Dasatinib, Imatinib, Nilotinib, Ponatinib)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D93CE5B6-87D7-2C7A-E053-4EBD850AAD5C","latestVersionIndicator":"Yes","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D93CE5B6-87F0-2C7A-E053-4EBD850AAD5C","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","deletedIndicator":"No"},{"value":"Bruton tyrosine Kinase (BTK) Inhibitors (Acalabrutinib, Ibtutinib, Zanubrutinib)","valueDescription":"Bruton tyrosine Kinase (BTK) Inhibitors (Acalabrutinib, Ibtutinib, Zanubrutinib)","ValueMeaning":{"publicId":"8067809","version":"1","preferredName":"Bruton tyrosine Kinase (BTK) Inhibitors (Acalabrutinib, Ibtutinib, Zanubrutinib)","longName":"8067809","preferredDefinition":"Bruton tyrosine Kinase (BTK) Inhibitors (Acalabrutinib, Ibtutinib, Zanubrutinib)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D93CE5B6-87FA-2C7A-E053-4EBD850AAD5C","latestVersionIndicator":"Yes","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D93CE5B6-8813-2C7A-E053-4EBD850AAD5C","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","deletedIndicator":"No"},{"value":"Ubiquitin proteasome pathway inhibitor (Bortezomib,  Carfilzomib, Ixazomib)","valueDescription":"Ubiquitin proteasome pathway inhibitor (Bortezomib,  Carfilzomib, Ixazomib)","ValueMeaning":{"publicId":"8067810","version":"1","preferredName":"Ubiquitin proteasome pathway inhibitor (Bortezomib,  Carfilzomib, Ixazomib)","longName":"8067810","preferredDefinition":"Ubiquitin proteasome pathway inhibitor (Bortezomib,  Carfilzomib, Ixazomib)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D93CE5B6-881D-2C7A-E053-4EBD850AAD5C","latestVersionIndicator":"Yes","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D93CE5B6-8836-2C7A-E053-4EBD850AAD5C","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7840169","version":"1","preferredName":"Targeted Therapy Type","preferredDefinition":"A type of treatment that uses drugs or other substances, such as monoclonal antibodies, to identify and attack specific cancer cells. Targeted therapy may have fewer side effects than other types of cancer treatments.:Something distinguishable as an identifiable class based on common qualities.","longName":"C93352:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Targeted Therapy","conceptCode":"C93352","definition":"A type of cancer treatment that uses testing and medication to more precisely identify and treat cancer. These treatments target and disable genes or proteins necessary to the proliferation of cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D1055049-1037-52B2-E053-4EBD850A5EA0","latestVersionIndicator":"Yes","beginDate":"2021-11-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-11-17","modifiedBy":"ONEDATA","dateModified":"2021-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D1055049-1048-52B2-E053-4EBD850A5EA0","latestVersionIndicator":"Yes","beginDate":"2021-11-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-11-17","modifiedBy":"COOPERJ","dateModified":"2022-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"What was the type of targeted","type":"Preferred Question Text","description":"What was the type of targeted therapy?","url":null,"context":"COG"},{"name":"COG CRF text 1","type":"Alternate Question Text","description":"Targeted Therapy Type:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D1056105-468D-2952-E053-4EBD850AADE6","latestVersionIndicator":"Yes","beginDate":"2021-11-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-11-17","modifiedBy":"MAESKEB","dateModified":"2022-03-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}